GlassScriptPhysician profile
Fayaz Asghar
NPI 1356530406
$2,061.27
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $141 · 2021: $919 · 2022: $595 · 2023: $99.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $99.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $99.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $650.54 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $528.40 | 2019-2022 | |
| Boston Scientific Corporation | $198.86 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $185.46 | 2019-2023 | Farxiga |
| Biotronik INC. | $130.85 | 2021 | |
| Pfizer INC. | $72.74 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $66.99 | 2021-2022 | |
| Novo Nordisk INC | $62.19 | 2022-2023 | Rybelsus, Ozempic |
| Actelion Pharmaceuticals US, INC. | $56.64 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.52 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $28.26 | 2022 | |
| Amgen INC. | $18.12 | 2020 | |
| Sanofi-Aventis U.S. LLC | $12.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fayaz Asghar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.